Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 1.00 |
| ▸ | BRD2 | P25440 | 1/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.68 |
| ▸ | TSPO | P30536 | 1/20 | 0.68 |
| ▸ | EP300 | Q09472 | 1/20 | 0.68 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.68 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22859376 | 1.00 | BRD4 (1.00) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL22859355 | 0.93 | BRD4 (0.87) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL26655735 | 0.92 | BRD4 (0.85) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL22859447 | 0.91 | BRD4 (0.84) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL22859405 | 0.89 | BRD4 (0.80) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL26655741 | 0.88 | BRD4 (0.78) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16658048 | 0.87 | BRD4 (0.77) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL26655743 | 0.87 | BRD4 (0.77) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL22859276 | 0.87 | BRD4 (0.77) | BRD4BRD2ADORA2BTSPOEP300 | |
| SCHEMBL16651923 | 0.86 | BRD4 (0.77) | BRD4BRD2ADORA2BTSPOEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276978-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2025-09-04 | — | — | US | disclosed |
| CN-114286818-B | Heterocyclic compounds as BET inhibitors | 诺维逊生物股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | NUVATION BIO INC. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3997070-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | Nuvation Bio Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-114286818-A | Heterocyclic compounds as BET inhibitors | 诺维逊生物股份有限公司 | 2022-04-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | BET1, BRD4, BRD3 | BRD4 2/4885BRD2 5/4885ADORA2B 4823/4885 |
| US-20250276978-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | BRD4 2/4885BRD2 5/4885ADORA2B 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.